20 November 2026
Linklaters advises banking syndicate on US$5.5bn SEC-registered bond issuances by Novartis
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Marco Carbonare Lead | Linklaters | Partner | Corporate/M&A | Not stated |
| Kevin Roy Lead | Linklaters | Counsel | Corporate/M&A | Not stated |
| Alexander Auster | Linklaters | Associate | Corporate/M&A | Not stated |
| Omer Harel | Linklaters | Counsel | Tax | Not stated |
| Alexander Gatlin | Linklaters | Associate | Corporate/M&A | Not stated |
| Marianna Troia | Linklaters | Associate | Corporate/M&A | Not stated |
| Helena Obenheimer | Linklaters | Associate | Capital markets | Not stated |
| Young Jin Kim | Linklaters | Associate | Tax | Not stated |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 5.50bn (US$5.5bn)
- What the figure measures
- Issue size
- Client
- global banking syndicateUnderwriters
- Counterparties
- Novartis Capital Corporation (Issuer)
Novartis AG (Issuer)